APP and Alzheimer disease: Therefore, we challenged the efficacy of the drug candidate RD2 by using it for the oral treatment of old-aged APP/PS1 transgenic AD mice exhibiting full-blown pathology, severe cognition impairments, and behavior deficits before the start of treatment.